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1  | INTRODUC TION





The	 incidence	 of	HCC	 is	 rising	 in	HIV/HCV	 co‐infected	 indi‐
viduals.1	 When	 ultrasonographic	 screening	 is	 performed	 every	
6	months,	HCC	may	be	diagnosed	in	an	earlier	stage	allowing	cu‐
rative	treatment.	Therefore,	 it	 is	 recommended	 in	multiple	 inter‐
national	guidelines	(AASLD,	EASL	and	EACS)	to	screen	individuals	
with	 cirrhosis	 twice	 a	 year	 with	 ultrasound	 for	 the	 presence	 of	
HCC.







2  | PATIENTS AND METHODS
2.1 | Study population
Individuals	 included	 in	 this	 study	 were	 enrolled	 in	 observational	
HIV	cohorts	participating	in	the	Collaboration	of	Observational	HIV	






who	 routinely	 document	 ultrasound	 results	 were	 collected.	 Four	
cohorts	 from	 Austria	 (Austrian	 HIV	 Cohort	 Study	 [AHIVCOS]),	
the	 Netherlands	 (AIDS	 Therapy	 Evaluation	 in	 the	 Netherlands	
[ATHENA]),	France	(French	national	prospective	cohort	of	patients	
co‐infected	with	HIV	 and	HCV	 [ANRS	CO13	HEPAVIH])	 and	 Italy	
(Hospital	San	Raffaele)	provided	data	for	our	analysis.
Patients	 were	 followed	 up	 starting	 1	 January	 2005	 until	 1	
January	2015.	HBV	co‐infection	was	defined	as	being	HBsAg‐pos‐
itive	and	HCV	co‐infection	as	HCV	antibody‐positive.	Assessment	
of	 liver	 cirrhosis	was	 based	on	 clinical	 diagnosis	 reported	 in	 the	
chart,	 liver	biopsy	or	Fibroscan	 result	 (≥18.1	 kPa	 for	HBV	 infec‐




defined	 as	 at	 least	 one	 ultrasound	 every	 6	months	 after	 the	 di‐
agnosis	of	 cirrhosis,	with	a	 two‐week	grace	period	 (6.5	months).	
Observation	time	started	from	the	date	of	cirrhosis	diagnosis	and	
continued	 until	 the	 first	 ultrasound	 and	 “re‐started”	 after	 each	
ultrasound.	Patients	were	censored	at	the	end	of	their	 last	com‐
plete	 observation	 period	 of	 6.5	months;	 in	 case,	 the	 last	 obser‐
vation	period	was	<6.5	months	because	of	the	database	closure,	
death	 or	 lost	 to	 follow‐up.	 Compliance	 was	 included	 as	 a	 time‐
varying	 outcome,	 and	 therefore,	 patients	 could	 switch	 between	
the	 compliance	and	noncompliance	groups.	Additionally,	 compli‐
ance	with	HCC	 screening	 guidelines	was	 assessed	 in	 relation	 to	














being	 screened,	we	used	 ‘time‐updated’	 age,	 increasing	 the	age	 in	
accordance	with	the	increase	in	follow‐up	time.
All	 variables	with	 a	P‐value	 <0.2	were	 considered	 as	 potential	
independent	 determinants	 and	 were	 included	 in	 the	 multivariate	
model.	A	P‐value	<0.05	was	considered	statistically	significant.	All	















The	 proportion	 of	 patients	 in	 whom	 HCC	 screening	 was	 per‐




2.59;	 95%	 CI	 1.80‐3.70),	 being	 HIV	 infected	 by	 IDU	 compared	
with	MSM	(OR	3.16;	95%	CI	2.18‐4.48),	 longer	duration	of	cART	
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HCV‐HIV	 co‐infection.	 In	 the	 multivariate	 analysis,	 longer	 fol‐
low‐up	after	cirrhosis	diagnosis	 (OR	1.59;	95%	CI	1.36‐1.87)	and	
cirrhosis	 diagnosis	 based	 on	 liver	 biopsy	 or	 Fibroscan	 (OR	1.68;	
1.11‐2.55)	remained	independently	associated	with	a	higher	com‐
pliance.	 Lack	 of	ALT	measurements	 (OR	0.52;	 95%	CI	 0.31‐0.86	














the	 rate	 of	 compliance	 did	 not	 change,	 and	 the	 results	 from	GEE	
analyses	 showed	 the	 same	associations	 as	when	data	 from	all	 co‐
horts	were	included.
Sensitivity	 analyses	 in	 which	 the	 screening	 intervals	 between	
ultrasounds	were	 increased	to	9	and	12	months	showed	a	varying	
compliance	 of	 7%	 (2005),	 12%	 (2006),	 17%‐18%	 (2007,	 2011)	 to	
20%‐24%	(2008‐2010	and	2012‐2014)	for	9‐month	intervals,	and	of	
7%	 (2005),	 14%	 (2006),	 20%	 (2007)	 to	 26%‐30%	 (2008‐2014)	 for	
12‐month	intervals.
Multivariate	 analysis	 performed	 after	 extending	 the	 permitted	
time	between	ultrasounds	 to	 9	months	 showed	 comparable	 asso‐
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following	 screening	 examinations	 geared	 towards	 HBV	 and/or	
HCV	care	may	be	missing,7	leading	to	patients	being	lost	to	follow‐
up.	 The	 frequency	 of	 clinic	 visits	 has	 been	 positively	 correlated	
with	adherence	to	HCC	screening	guidelines	 in	earlier	studies.4,5 
Our	study	seems	 to	confirm	this,	as	we	 found	 that	 frequency	of	
clinical	visits,	ALT	and	HIV‐RNA	measurements,	 is	positively	cor‐
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